In models of acute brain injury, progesterone improves recovery through several mechanisms including modulation of neuroinflammation. Secondary injury from neuroinflammation is a potential therapeutic target after intracerebral hemorrhage (ICH). For potential translation of progesterone as a clinical acute ICH therapeutic, the present study sought to define efficacy of exogenous progesterone administration in ICH-relevant experimental paradigms. Young and aged C57BL/6 male, female, and ovariectomized (OVX) mice underwent left intrastriatal collagenase (0.05-0.075 U) or autologous whole blood (35 μl) injection. Progesterone at varying doses (4-16 mg/kg) was administered at 2, 5, 24, 48, and 72 h after injury. Rotarod and Morris water maze latencies were measured on days 1-7 and days 28-31 after injury, respectively. Hematoma volume, brain water content (cerebral edema), complementary immunohistochemistry, multiplex cytokine arrays, and inflammatory proteins were assessed at prespecified time points after injury. Progesterone (4 mg/kg) administration improved rotarod and water maze latencies (p < 0.01), and decreased cerebral edema (p < 0.05), microglial proliferation, and neuronal loss (p < 0.01) in young and aged male, young OVX, and aged female mice. Brain concentration of proinflammatory cytokines and Toll-like receptor-associated proteins were also decreased after progesterone (4 mg/kg) treatment (p < 0.01). Progesterone-treated young female mice showed no detectable effects. Exogenous progesterone improved short- and long-term neurobehavioral recovery and modulated neuroinflammation in male and OVX mice after ICH. Future studies should validate these findings, and address timing and length of administration before translation to clinical trial.

1.
Lee HY, Hwang JS, Jeng JS, Wang JD: Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke 2010;41:739-744.
2.
Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM; STICH II Investigators: early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013;382:397-408.
3.
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, Investigators FT: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358:2127-2137.
4.
Ganti L, Jain A, Yerragondu N, Jain M, Bellolio MF, Gilmore RM, Rabinstein A: Female gender remains an independent risk factor for poor outcome after acute nontraumatic intracerebral hemorrhage. Neurol Res Int 2013;2013:219097.
5.
Gokhale S, Caplan LR, James ML: Sex differences in incidence, pathophysiology, and outcome of primary intracerebral hemorrhage. Stroke 2015;46:886-892.
6.
Umeano O, Phillips-Bute B, Hailey CE, Sun W, Gray MC, Roulhac-Wilson B, McDonagh DL, Kranz PG, Laskowitz DT, James ML: Gender and age interact to affect early outcome after intracerebral hemorrhage. PLoS One 2013;8:e81664.
7.
Lei B, Mace B, Bellows ST, Sullivan PM, Vitek MP, Laskowitz DT, James ML: Interaction between sex and apolipoprotein e genetic background in a murine model of intracerebral hemorrhage. Transl Stroke Res 2012;3:94-101.
8.
Chen Z, Xi G, Mao Y, Keep RF, Hua Y: Effects of progesterone and testosterone on ICH-induced brain injury in rats. Acta Neurochir Suppl 2011;111:289-293.
9.
Grossman KJ, Goss CW, Stein DG: Effects of progesterone on the inflammatory response to brain injury in the rat. Brain Res 2004;1008:29-39.
10.
Habib P, Dreymueller D, Ludwig A, Beyer C, Dang J: Sex steroid hormone-mediated functional regulation of microglia-like BV-2 cells during hypoxia. J Steroid Biochem Mol Biol 2013;138:195-205.
11.
Hwang-Levine J, Stanczyk FZ, Hodis HN: The role of progestogens in regulating matrix metalloproteinase activity in macrophages and microglial cells. Neurochem Res 2011;36:1870-1875.
12.
Jiang C, Cui K, Wang J, He Y: Microglia and cyclooxygenase-2: possible therapeutic targets of progesterone for stroke. Int Immunopharmacol 2011;11:1925-1931.
13.
Mracsko E, Veltkamp R: Neuroinflammation after intracerebral hemorrhage. Front Cell Neurosci 2014;8:388.
14.
Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, Nelson NR, Stocchetti N; SYNAPSE Trial Investigators: A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med 2014;371:2467-2476.
15.
Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, Janis LS, Barsan WG; NETT Investigators: Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 2014;371:2457-2466.
16.
Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group: Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-2250.
17.
Lapchak PA, Zhang JH, Noble-Haeusslein LJ: RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res 2013;4:279-285.
18.
Cutler SM, Cekic M, Miller DM, Wali B, Van Landingham JW, Stein DG: Progesterone improves acute recovery after traumatic brain injury in the aged rat. J Neurotrauma 2007;24:1475-1486.
19.
Fata JE, Chaudhary V, Khokha R: Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod 2001;65:680-688.
20.
Wood GA, Fata JE, Watson KL, Khokha R: Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction 2007;133:1035-1044.
21.
Harrison DE: Lifespan as a biomarker. http://research.jax.org/faculty/harrison/ger1vLifespan1.html. Jackson Laboratories, 2012, 2014.
22.
Caligioni CS: Assessing reproductive status/stages in mice. Curr Protoc Neurosci 2009;Appendix 4:Appendix 4I.
23.
Lei B, Sheng H, Wang H, Lascola CD, Warner DS, Laskowitz DT, James ML: Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage. J Vis Exp DOI: 10.3791/51439.
24.
Deinsberger W, Hartmann M, Vogel J, Jansen O, Kuschinsky W, Sartor K, Boker DK: Local fibrinolysis and aspiration of intracerebral hematomas in rats. An experimental study using MR monitoring. Neurol Res 1998;20:349-352.
25.
Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW: The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994;11:187-196.
26.
Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
27.
Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G: Behavioral tests after intracerebral hemorrhage in the rat. Stroke 2002;33:2478-2484.
28.
Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC: The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001;32:891-897.
29.
Yang J, Arima H, Wu G, Heeley E, Delcourt C, Zhou J, Chen G, Wang X, Zhang S, Yu S, Chalmers J, Anderson CS; INTERACT Investigators: Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the intensive blood pressure reduction in acute cerebral hemorrhage trial studies. Stroke 2015;46:1009-1013.
30.
West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482-497.
31.
James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT: Pharmacogenomic effects of apolipoprotein E on intracerebral hemorrhage. Stroke 2009;40:632-639.
32.
Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, Maze M, Franks NP, Pearlstein RD, Sheng H, Warner DS: Xenon neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage. Anesthesiology 2012;117:1262-1275.
33.
Chen TY, Tsai KL, Lee TY, Chiueh CC, Lee WS, Hsu C: Sex-specific role of thioredoxin in neuroprotection against iron-induced brain injury conferred by estradiol. Stroke 2010;41:160-165.
34.
Nakamura T, Xi G, Keep RF, Wang M, Nagao S, Hoff JT, Hua Y: Effects of endogenous and exogenous estrogen on intracerebral hemorrhage-induced brain damage in rats. Acta Neurochir Suppl 2006;96:218-221.
35.
Manwani B, Bentivegna K, Benashski SE, Venna VR, Xu Y, Arnold AP, McCullough LD: Sex differences in ischemic stroke sensitivity are influenced by gonadal hormones, not by sex chromosome complement. J Cereb Blood Flow Metab 2015;35:221-229.
36.
Mirza MA, Ritzel R, Xu Y, McCullough LD, Liu F: Sexually dimorphic outcomes and inflammatory responses in hypoxic-ischemic encephalopathy. J Neuroinflamm 2015;12:32.
37.
James ML, Warner DS, Laskowitz DT: Preclinical models of intracerebral hemorrhage: a translational perspective. Neurocrit Care 2008;9:139-152.
38.
Soderpalm AH, Lindsey S, Purdy RH, Hauger R, Wit de H: Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 2004;29:339-354.
39.
Baudry M, Bi X, Aguirre C: Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience 2013;239:280-294.
40.
Atif F, Sayeed I, Yousuf S, Ishrat T, Hua F, Wang J, Brat DJ, Stein DG: Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence. Mol Med 2011;17:1084-1094.
41.
Chen G, Shi J, Ding Y, Yin H, Hang C: Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats. Mediat Inflamm 2007;2007:93431.
42.
Chen G, Shi J, Jin W, Wang L, Xie W, Sun J, Hang C: Progesterone administration modulates TLRs/NF-kappaB signaling pathway in rat brain after cortical contusion. Ann Clin Lab Sci 2008;38:65-74.
43.
Pettus EH, Wright DW, Stein DG, Hoffman SW: Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005;1049:112-119.
44.
Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J: Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008;149:3167-3175.
45.
Appelboom G, Bruce S, Duren A, Piazza M, Monahan A, Christophe B, Zoller S, LoPresti M, Connolly ES: Aquaporin-4 gene variant independently associated with oedema after intracerebral haemorrhage. Neurol Res 2015;37:657-661.
46.
Guo Q, Sayeed I, Baronne LM, Hoffman SW, Guennoun R, Stein DG: Progesterone administration modulates AQP4 expression and edema after traumatic brain injury in male rats. Exp Neurol 2006;198:469-478.
47.
Su L, Sun Y, Ma F, Lu P, Huang H, Zhou J: Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-kappaB activation and enhancing SOCS1 expression. Immunol Lett 2009;125:151-155.
48.
Wang Z, Zuo G, Shi XY, Zhang J, Fang Q, Chen G: Progesterone administration modulates cortical TLR4/NF-kappaB signaling pathway after subarachnoid hemorrhage in male rats. Mediat Inflamm 2011;2011:848309.
49.
Schwamm LH: Progesterone for traumatic brain injury - resisting the sirens' song. N Engl J Med 2014;371:2522-2523.
50.
Warner DS, James ML, Laskowitz DT, Wijdicks EF: Translational research in acute central nervous system injury: lessons learned and the future. JAMA Neurol 2014;71:1311-1318.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.